The New Steatotic Liver Disease Subclassification and the New MASH-targeted Pharmacotherapy: Resmetirom

By Maria Nikki Cruz, MD Steatotic Liver Disease (SLD) has various etiologies (Figure 1). Metabolic dysfunction-associated steatotic liver disease (MASLD),